Electromed, Inc. (NYSE American: ELMD), a Minnesota-based medical device company, carries a modest but active sell-side following. Three current analyst price targets form the basis of the central figure used here: Lake Street raised its target to $47 from $36 on August 26, 2026, reiterating a Buy; Freedom Broker set a $50 target on the same date; and B. Riley Securities moved to $40 from $38 on May 13, 2026, also with a Buy rating. Averaging these three values yields $45.67, rounded to a clean $46.
The range spans $40 to $50, and all three firms carry constructive ratings. The reasoning is consistent: Electromed's direct-to-patient model, expanding payer coverage, and a large, under-treated bronchiectasis population support durable double-digit growth. The spread between the lowest and highest targets is less about disagreement over the business and more about the valuation multiple each firm assigns to a fast-growing, single-product small-cap. It is important to note that $46 is a calculated average, not an official published consensus.
At its latest verified close near $27.06, ELMD trades roughly 70% below the central $46 target. That gap qualifies as a very large required move, and it reflects a notable disconnect between the stock's recent trading range — the 52-week span is $23.01 to $47.40 — and where analysts see fair value.
The fundamental backdrop supports the higher figures. For fiscal 2026, Electromed reported record net revenue of $73.8 million, up 15.3% year over year, net income of $11.3 million ($1.30 per diluted share), and an operating margin of 18.8%, up more than 370 basis points. Gross margin sits in the high-70s, and the company holds about $20.5 million in cash with no debt. Management guided to double-digit revenue growth and continued operating leverage for fiscal 2027.
The 52-week range of $23.01 to $47.40 defines the key technical boundaries. The lower end near $23 has acted as support, while the $47 area — just below the $47.40 prior high — represents a major resistance zone that coincides with Lake Street's target. The central $46 target sits essentially at that resistance level, meaning a move to $46 would require the stock to reclaim and hold territory it surrendered after reaching its 2026 peak. A psychological threshold at $30 is the first meaningful level overhead on any recovery path.
Analyst price targets typically reflect a roughly 12-month horizon, though no firm published a precise time frame here. The most important near-term catalyst is Electromed's next earnings report and updated guidance, where investors will look for continued double-digit growth and confirmation of operating leverage. Other items to watch include analyst revisions following results, sales-representative productivity, payer-contract additions, any update on the CEO succession, and broader small-cap and healthcare sector sentiment.
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap like Electromed, this kind of automated monitoring can help traders surface opportunities, keep tabs on existing positions, and spot shifting trends more efficiently than manual chart review. Explore the signals to see how the AI is reading ELMD's current setup.
The central $46 target — an average of three current analyst targets ranging from $40 to $50 — implies a roughly 70% advance from the latest price near $27, a very large move that hinges on the market assigning a higher valuation to a business already delivering double-digit growth, high margins, and no debt. The supports are tangible: an underpenetrated bronchiectasis market, expanding reimbursement, and consistent operational leverage. The obstacles are equally real: single-product risk, small-cap volatility, a looming CEO transition, and the wide gap between the stock's recent trading and analyst fair-value estimates. Whether the shares close that gap depends on sustained execution and a re-rating by investors, neither of which is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ELMD has been loosely correlated with KRMD. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ELMD jumps, then KRMD could also see price increases.
| Ticker / NAME | Correlation To ELMD | 1D Price Change % | ||
|---|---|---|---|---|
| ELMD | 100% | -8.17% | ||
| KRMD - ELMD | 34% Loosely correlated | +23.10% | ||
| SMTI - ELMD | 32% Poorly correlated | -0.16% | ||
| INBS - ELMD | 31% Poorly correlated | -6.67% | ||
| RVTY - ELMD | 30% Poorly correlated | -0.53% | ||
| BDSX - ELMD | 30% Poorly correlated | +1.00% | ||
More | ||||
| Ticker / NAME | Correlation To ELMD | 1D Price Change % |
|---|---|---|
| ELMD | 100% | -8.17% |
| Health Services category (239 stocks) | -1% Poorly correlated | -0.30% |
| Medical/Nursing Services category (138 stocks) | -2% Poorly correlated | +1.72% |